title: Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.
abstract: OBJECTIVE
  To evaluate the effect and safety of HbA1c and glycemic control of acarbose chewable tablets in patients with type 2 diabetic.
  
  
  METHODS
  A multicentre, randomized, double-blinded, double-dummy, positive controlled clinical trial was conducted. Two hundred thirty-four Chinese patients with type 2 diabetic were enrolled in eight clinical centres, who were divided randomly into the acarbose chewable tablet group (experimental group, n = 116) and the acarbose treatment group (control group, n = 118).
  
  
  RESULTS
  Two hundred seven patients (88.5%) took part in the 12-week trial. At the beginning and end of the clinical trial, HbA1c and blood glucose as well as safety indexes were measured. After the treatment, the level of finger two-hour postprandial blood glucose (PPBG) was decreased 4.15 mmol/L (26.82%) and 3.54 mmol/L (22.77%), respectively, in the experiment group and the control group. The levels of venous two-hour PPBG in the experiment group and the control group were decreased 4.04 mmol/L (25.38%) and 2.75 mmol/L (17.26%), respectively, with the means of HbA1c lowering 11.67% and 12.44%, respectively. Fasting blood glucose (FBG) also was reduced significantly in both groups. Patients in both groups showed obvious weight reduction (P < 0.0001). There were no significant differences in the incidence of adverse events between the two groups.
  
  
  CONCLUSIONS
  In summary, acarbose chewable tablets have a definite curative effect in treating type 2 diabetic patients as HbA1c and blood glucose levels decreased significantly after the 12-week treatment.
authors.affiliation: Department of Endocrinology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Qian Lin
authors.initials: QL
authors.lastname: Wu
authors.forename: Yu Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Ju Ming
authors.initials: JM
authors.lastname: Lu
authors.forename: Chang Jiang
authors.initials: CJ
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.forename: Ji Xiang
authors.initials: JX
authors.lastname: Dong
authors.forename: Cheng Jiang
authors.initials: CJ
authors.lastname: Li
authors.forename: Jian Hua
authors.initials: JH
authors.lastname: Ma
authors.forename: Yao Ming
authors.initials: YM
authors.lastname: Xue
authors.forename: Rui Hua
authors.initials: RH
authors.lastname: Sun
authors.forename: Dong
authors.initials: D
authors.lastname: Wei
authors.forename: Hao Ming
authors.initials: HM
authors.lastname: Tian
mesh_terms: D020909:Acarbose / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human